



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : David Potter Art Unit : 1642
Serial No. : 10/629,045 Examiner : Unknown
Filed : July 28, 2003
Title : METHODS OF TREATING CANCER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449.

This statement is being filed within three months of the filing date of the application or before the receipt of a first Office action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing attorney docket number 05524-003001.

Respectfully submitted,

Date: March 2, 2003



Catherine M. McCarty
Reg. No. 54,301

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20815467.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL


I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

March 2, 2004

Date of Deposit



Signature



Typed or Printed Name of Person Signing Certificate

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 05524-003001	Application No. 10/629,045
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant David Potter			
		Filing Date July 28, 2003		Group Art Unit 1642	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AC							
	AD							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AE	Andre, Patrice, et al., "An Inhibitor of HIV-1 Protease Modulates Proteasome Activity, Antigen Presentation, and T Cell Responses," <i>Proc. National Academy Science USA</i> , Vol. 95: 13120-13124 (1998).
	AF	Carragher, N. O., et al., "v-Src-Induced Modulation of the Calpain-Calpastatin Proteolytic System Regulates Transformation," <i>Molecular and Cellular Biology</i> , p. 257-269 (2002).
	AG	Fenteany, Gabriel, et al., "Inhibition of Proteasome Activities and Subunit-Specific Amino-Terminal Threonine Modification by Lactacystin," <i>Science</i> , Vol. 268, No. 5211: 726-731 (1995).
	AH	Gaedicke, Simone, et al., "Antitumor Effect of the Human Immunodeficiency Virus Protease Inhibitor Ritonavir: Induction of Tumor-Cell Apoptosis Associated with Perturbation of Proteasomal Proteolysis," <i>Cancer Research</i> , Vol. 62: 6901-6908 (2002).
	AI	Glading, Angela, et al., "Membrane Proximal ERK Signaling is Required for M-calpain Activation Downstream of Epidermal Growth Factor Receptor Signaling," <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 26: 23341-23348 (2001).
	AJ	Hehner, Steffen, P., et al., "The Antiinflammatory Sesquiterpene Lactone Parthenolide Inhibits NF- κ B by Targeting the I κ B Kinase Complex," <i>The American Association of Immunologists</i> , Vol. 163: 5617-5623 (1999).
	AK	Holmes-McNary, Minni, et al., "Chemopreventive Properties of trans-Resveratrol are Associated with Inhibition of Activation of the I κ B Kinase," <i>Cancer Research</i> , Vol. 60: 3477-3483 (2000).
	AL	Kubbutat, Michael H.G., "Proteolytic Cleavage of Human p53 by Calpain: a Potential Regulator of Protein Stability," <i>Molecular and Cellular Biology</i> p. 460-468 (1997).
	AM	Liu, Catherine H., et al. "Overexpression of Cyclooxygenase-2 is Sufficient to Induce Tumorigenesis in Transgenic Mice," <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 21: 18563-18569 (2001).
	AN	Pati, Shibani, et al. "Antitumorigenic Effects of HIV-Protease Inhibitor Ritonavir: Inhibition of Kaposi Sarcoma," <i>The American Society of Hematology</i> , Vol. 99, No. 10: 3771-3779 (2002).
	AO	Ross, T. Douglas, et al., "Systematic Variation in Gene Expression Patterns in Human Cancer Cell Lines," <i>Nature Genetics</i> , Vol. 24: 227-235 (2000).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 05524-003001	Application No. 10/629,045
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant David Potter	
		Filing Date July 28, 2003	Group Art Unit 1642

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AP	Shiba, Eiichi, et al., "Mechanism of Growth Inhibition by Calpain Inhibitor in MCF-7 Cells," <i>Anticancer Research</i> , Vol. 17: 1919-1924 (1997).
	AQ	Shiba, Eiichi, et al., "Possible Involvement of Calpain in the Growth of Estrogen Receptor Positive Breast Cancer Cells," <i>Anticancer Research</i> Vol. 16: 773-778 (1996).
	AR	Schoenwaelder, Simone M., et al., "Evidence for a Calpeptin-sensitive Protein-tyrosine Phosphatase Upstream of the Small GTPase Rho," <i>The Journal of Biological Chemistry</i> , Vol. 274, No. 20: 14359-14367 (1999).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	